FrancophonIA/ELRC3.0 huggingface dataset:
English: Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Slovenian: Nevirapin spada v skupino anti-HIV zdravil, imenovani nenukleozidni zaviralci reverzne transkriptaze (NNRTI).
English: Pharmacokinetic results suggest caution should be exercised when nevirapine is administered to patients with moderate hepatic dysfunction (Child-Pugh B).
Slovenian: Farmakokinetični podatki kažejo, da moramo biti previdni, kadar dajemo nevirapin bolnikom z zmerno jetrno disfunkcijo (Child-Pugh C).
English: PHARMACEUTICAL FORM AND CONTENTS Treatment initiation pack containing 14 tablets
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA Zdravljenje: pakiranje za začetno zdravljenje s 14 tabletami.
English: Anaphylactic reaction was identified through post-marketing surveillance but not observed in randomised, controlled clinical studies.
Slovenian: Anafilaktično reakcijo so odkrili med nadzorom zdravila po začetku trženja, ne pa tudi v nadzorovanih kliničnih študijah z naključno izbranimi bolniki.
English: In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection (AIDS defining illness), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Slovenian: Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS) in z oportunistično okužbo (bolezen, katero definira AIDS) v anamnezi se lahko kmalu po začetku anti-HIV zdravljenja pojavijo znaki in simptomi vnetja povezani s prejšnjimi okužbami.
English: Physicians and patients should be vigilant for prodromal signs or findings of hepatitis, such as anorexia, nausea, jaundice, bilirubinuria, acholic stools, hepatomegaly or liver tenderness.
Slovenian: Zdravniki in bolniki morajo biti pozorni na prodromske znake ali izvide, ki kažejo na hepatitis, kot so anoreksija, slabost, zlatenica, bilirubinurija, aholično blato, hepatomegalija ali občutljivost jeter.
English: Once daily
Slovenian: peroralna uporaba enkrat na dan
English: Weight Range (kg) for patients  8 years of age on a body weight basis receiving 4 mg/kg.
Slovenian: Razpon telesne mase (kg) za bolnike  8 let starosti, ki prejemajo na podlagi telesne mase odmerke po 4 mg/kg
English: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Slovenian: Bolniki z redkim, dednim neprenašanjem fruktoze, malabsorpcijo glukoze-galaktoze ali pomanjkanjem saharoze-izomaltaze zdravila ne smejo jemati.
English: ANTIBIOTICS Clarithromycin 500 mg BID
Slovenian: Antibiotiki Klaritromicin 500 mg 2-krat na dan
English: The pharmacokinetics of autoinduction is characterized by an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day.
Slovenian: Za farmakokinetiko samoindukcije je značilno približno 1,5- do 2-kratno povečanje navideznega očistka peroralnega nevirapina, ko zdravljenje z začetnim enkratnim odmerkom nadaljujemo dva do štiri tedne z odmerki po 200 do 400 mg na dan.
English: As Viramune must always be taken together with other HIV antiretroviral medicines, you should follow the instructions for your other medicines carefully.
Slovenian: Ker je treba zdravilo Viramune vedno jemati skupaj z drugimi protiretrovirusnimi zdravili proti HIV, morate upoštevati tudi navodila za druga zdravila.
English: The NEFA study is a controlled prospective randomised study which evaluated treatment options for patients who switch from protease inhibitor (PI) based regimen with undetectable load to either Viramune, efavirenz or abacavir.
Slovenian: Študija NEFA je nadzorovana, prospektivna študija z naključno izbiro bolnikov, v kateri so ocenjevali možne načine zdravljenja bolnikov z nedokazljivim bremenom, pri katerih zamenjajo zaviralec proteaze za zdravilo Viramune, efavirenz ali abakavir.
English: Nevirapine must be permanently discontinued in any patient experiencing severe rash or a rash accompanied by constitutional symptoms (such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise), including Stevens-Johnson syndrome, or toxic epidermal necrolysis.
Slovenian: Nevirapin moramo dokončno ukiniti vsem bolnikom, pri katerih so se pojavili hud izpuščaj ali izpuščaj ob hkratnih splošnih simptomih (npr. vročini, mehurčkih, lezijah v ustni votlini, konjunktivitisu, obraznem edemu, mišičnih ali sklepnih bolečinah ali splošnem slabem počutju), vključujoč Stevens-Johnsonov sindrom ali toksično epidermalno nekrolizo.
English: Coadministration with herbal preparations containing St. John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Slovenian: Sočasno jemanje zeliščnih pripravkov, ki vsebujejo šentjanževko (Hypericum perforatum), ker lahko zmanjšajo koncentracijo nevirapina v plazmi in njegove klinične učinke (glejte poglavje 4.5).
English: How to take Viramune
Slovenian: Kako jemati zdravilo Viramune
English: A marked improvement in the CD4+ cell percent was observed through Week 48 for both dose groups.
Slovenian: V obeh skupinah z različnima odmerkoma se je odstotek celic CD4+ do 48. tedna zaznavno izboljšal.
English: Increased ASAT or ALAT levels > 2.5 ULN and/or co-infection with hepatitis B and/or C at the start of antiretroviral therapy is associated with greater risk of hepatic adverse reactions during antiretroviral therapy in general, including nevirapine containing regimens.
Slovenian: Povečana raven ASAT ali ALAT na ≥ 2,5-kratno zgornjo mejo normalne laboratorijske vrednosti ali sočasna okužba z virusom hepatitisa B ali C ali oboje na začetku protivirusnega zdravljenja sta na splošno povezani z večjim tveganjem neželenih učinkov na jetra med protivirusnim zdravljenjem, tudi s takšnim, v sklopu katerega je nevirapin.
English: Because nevirapine induces its own metabolism with multiple dosing, this single dose study may not reflect the impact of hepatic impairment on multiple dose pharmacokinetics (see section 4.4).
Slovenian: Nevirapin ob večkratnem odmerjanju inducira svoje lastno presnavljanje, zato ta študija, v kateri so uporabili enkratno odmerjanje, ni pokazala vpliva jetrne okvare na farmakokinetiko, kot se sicer dogaja ob večkratnem dajanju zdravila (glejte poglavje 4.4).
English: Most of the cases of both severe rash and mild/moderate rash occur in the first six weeks of treatment.
Slovenian: Hud pa tudi blag ali zmerno hud izpuščaj se večinoma pojavi v prvih šestih tednih zdravljenja.
English: Each 5 ml contains 50 mg of the active substance nevirapine (as hemihydrate).
Slovenian: Pet millilitrov vsebuje 50 mg učinkovine nevirapina (v obliki hemihidrata).
English: The relative bioavailability of nevirapine when dosed as one 400 mg Viramune prolonged-release tablet, relative to two 200 mg Viramune immediaterelease tablets, was approximately 75 %.
Slovenian: Relativna biološka uporabnost nevirapina je bila po eni 400 mg tableti zdravila Viramune s podaljšanim sproščanjem, v primerjavi z dvema 200 mg tabletama zdravila Viramune s takojšnjim sproščanjem približno 75-odstotna.
English: The most that you can withdraw is 5 ml at a time.
Slovenian: Naenkrat lahko odvzamete največ 5 ml suspenzije.
English: Some risk factors for developing serious cutaneous reactions have been identified, they include failure to follow the initial dosing of 200 mg daily (4 mg/kg or 150 mg/m2 for paediatric patients) during the lead-in period and a long delay between the initial symptoms and medical consultation.
Slovenian: Znanih je nekaj dejavnikov tveganja za razvoj resnih kožnih reakcij, med njimi neupoštevanje začetnega odmerjanja po 200 mg na dan (4 mg/kg ali 150 mg/m2 pri otrocih) v uvajalnem obdobju zdravljenja in daljši odlog od pojava prvih simptomov do obiska zdravnika.
English: Viramune 100 mg prolonged-release tablets can be taken by children three years of age and above.
Slovenian: Zdravilo Viramune 100 mg tablete s podaljšanim sproščanjem lahko jemljejo otroci, stari tri leta in starejši.
English: Baseline CD4 count (cells/mm - Mean (SD)
Slovenian: Izhodiščno število CD4 (celic/mm - srednja vrednost (SD)
English: Nevirapine Cmax  0.50 compared to historical controls.
Slovenian: Cmax nevirapina  0,50 v primerjavi s prejšnjimi, kontrolnimi vrednostmi
English: Thereafter your child will be switched to a twice daily dosing schedule and your child's doctor will decide the right dose based either on your child's weight or body surface area.
Slovenian: Nato bodo pri otroku prešli na shemo odmerjanja z dajanjem dvakrat na dan, otrokov zdravnik pa bo ustrezni odmerek določil na podlagi telesne mase ali površine vašega otroka.
English: For paediatric patients aged 3 years and older, 100 mg prolonged-release tablets are available.
Slovenian: Za otroke, starejše od 3 let, so na voljo 100 mg tablete s podaljšanim sproščanjem.
English: ENTRY INHIBITORS Enfuvirtide
Slovenian: Fuzijski zaviralci (zaviralci zlitja) Enfuvirtid
English: If an alternative measuring device is used (e.g. a dispensing cup or teaspoon for larger doses) it is important that the device is rinsed to ensure complete removal of residual oral suspension.
Slovenian: Če uporabimo drugačen pripomoček za odmerjanje (npr. merilno posodico ali malo žlico za večje odmerke), ga moramo splakniti, da bi uporabili vso preostalo peroralno suspenzijo.
English: An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm
Slovenian: Povečano tveganje so zasledili tudi pri moških z izmerljivo ravnijo HIV-1 RNA v plazmi in s številom celic CD4 > 400 celic/mm
English: Nevirapine Cmin  1.28
Slovenian: Cmin nevirapina  1,28
English: Patients have experienced oedema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting, increase in transaminases and weight decrease.
Slovenian: Pri bolnikih je povzročilo edeme, nodozne eriteme, utrujenost, vročino, glavobol, nespečnost, slabost, pljučne infiltrate, izpuščaj, vrtoglavico, bruhanje, povečanje transaminaz in zmanjšanje telesne mase.
English: The use of Viramune has not been evaluated within a specific study on PEP, especially in term of treatment duration and therefore, is strongly discouraged.
Slovenian: V tem primeru za zdravilo Viramune niso opravili specifične raziskave o profilaktični uporabi po izpostavljenosti okužbi, zlasti ne glede na trajanje takšnega zdravljenja, ter je zato taka uporaba močno odsvetovana.
English: EE AUC  0.80 (0.67 - 0.97) EE Cmin ND
Slovenian: AUC EE  0,80 (0,67-0,97) Cmin EE ND
English: Nevirapine Cmin  1.07
Slovenian: Cmin nevirapina  1,07
English: If you experience symptoms suggesting damage of the liver, such as - loss of appetite, - feeling sick (nausea), - vomiting, - yellow skin (jaundice), - abdominal pain you should discontinue taking Viramune and must contact your doctor immediately.
Slovenian: Če se pojavijo simptomi, ki kažejo na poškodbo jeter, kot so: - zmanjšan tek - občutek slabosti (siljenje na bruhanje) - bruhanje - rumena koža (zlatenica) - trebušne bolečina, morate prenehati jemati zdravilo Viramune in se nemudoma posvetovati s svojim zdravnikom.
English: In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6%).
Slovenian: V dvojno slepi s placebom nadzorovani raziskavi ACTG 245 so resno, z zdravilom povezano, granulocitopenijo zasledili pri 5 od 305 bolnikov (1,6 %).
English: An increase in the dose of lopinavir/ritonavir to 533/133 mg (4 capsules) or 500/125 mg (5 tablets with 100/25 mg each) twice daily with food is recommended in combination with Viramune.
Slovenian: Pri kombiniranju z zdravilom Viramune priporočajo povečanje odmerka lopinavirja z ritonavirjem do 533/133 mg (4 kapsule) ali 500/125 mg (5 tablet po 100/25 mg) 2-krat na dan ob jedi.
English: NET AUC  0.81 (0.70 - 0.93) NET Cmin ND
Slovenian: AUC NET  0,81 (0,70-0,93) Cmin NET ND
English: If patients present with a suspected nevirapine-associated rash, liver function tests should be performed.
Slovenian: Bolnikom, pri katerih sumimo, da imajo z nevirapinom povezan izpuščaj, moramo opraviti preiskave jetrne funkcije.
English: Viramune is also available as an oral suspension, tablets or as prolonged-release tablets with lower strength.
Slovenian: Zdravilo Viramune je na voljo tudi v obliki peroralne suspenzije, tablet ali tablet s podaljšanim sproščanjem v nižji jakosti.
English: Alternatives to clarithromycin, such as azithromycin should be considered.
Slovenian: Presoditi je treba o uporabo alternativnih zdravil namesto klaritromicina, na primer azitromicina.
English: Women of childbearing potential / Contraception in males and females Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 & 4.5).
Slovenian: Ženske v rodni dobi / kontracepcija pri moških in ženskah Ženske v rodni dobi peroralnih kontraceptivov ne smejo uporabljati kot edine metode za nadzor rojstev, ker lahko nevirapin zmanjša njihovo koncentracijo teh zdravil v plazmi (glejte poglavji 4.4 in
English: White, oval, biconvex tablets.
Slovenian: Bele, ovalne bikonveksne tablete.
English: Viramune is also available as an oral suspension, tablets or as prolonged-release tablets with higher strength.
Slovenian: Zdravilo Viramune je na voljo tudi v obliki peroralne suspenzije, tablet ali tablet s podaljšanim sproščanjem v višji jakosti.
English: Tell your doctor immediately if you experience rash and any of the other side effects of a hypersensitivity (allergic) reaction.
Slovenian: Svojega ali otrokovega zdravnika nemudoma obvestite, če pri sebi ali svojemu otroku opazite izpuščaj, ali katerega od ostalih znakov preobčutljivostne (alergijske) reakcije.
English: Weight Range (kg) for patients < 8 yrs of age on a body weight basis receiving 7 mg/kg.
Slovenian: Razpon telesne mase (kg) za bolnike <8 let starosti, ki prejemajo na podlagi telesne mase odmerke po 7 mg/kg
English: The medicinal product should be used within 2 months of opening.
Slovenian: Odprto zdravilo je treba porabiti v 2 mesecih.
English: INTEGRASE INHIBITORS Elvitegravir/ cobicistat
Slovenian: Zaviralci integraze Elvitegravir/ kobicistat
English: Physicians needing to treat patients co-infected with tuberculosis and using a Viramune containing regimen may consider coadministration of rifabutin instead.
Slovenian: Zdravniki, ki zdravijo bolnike s sočasno tuberkulozo in v sklopu zdravljenja uporabljajo zdravilo Viramune, lahko presodijo o sočasnem dajanju z rifabutinom.
English: Patients experiencing rash during the 14-day lead-in period of 200 mg/day (4 mg/kg/day or 150 mg/m2/day for paediatric patients) should not have their Viramune dose increased until the rash has resolved.
Slovenian: Bolnikom, pri katerih se med 14-dnevnim uvajalnim obdobjem z odmerki po 200 mg na dan (4 mg/kg na dan ali 150 mg/m2 na dan pri otrocih) pojavi izpuščaj, odmerka zdravila Viramune ne smemo povečati, dokler izpuščaj ne mine.
English: Each bottle contains 240 ml of oral suspension.
Slovenian: Ena plastenka vsebuje 240 ml peroralne suspenzije.
English: Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at
Slovenian: Po odmerjanju nevirapina dvakrat dnevno po 150 mg/m2 (po dvotedenskem uvajanju z odmerki po
English: If Viramune has been prescribed for your child, please note that all information in this leaflet is addressed to your child (please read “your child” instead of “you”).
Slovenian: Če je bilo zdravilo Viramune predpisano vašemu otroku, prosimo upoštevajte, da vse informacije v tem navodilu veljajo samo za vašega otroka (“vi” berite kot “vaš otrok”).
English: The lead-in period is not required if the patient is already on chronic Viramune 200 mg tablets or Viramune oral suspension twice daily treatment.
Slovenian: Uvajalno obdobje ni potrebno, če se bolnik že zdravi z zdravilom Viramune 200 mg tablete ali zdravilom Viramune 50 mg/5ml peroralna suspenzija , ki ju jemlje dvakrat dnevno.
English: No observable teratogenicity was detected in reproductive studies performed in pregnant rats and rabbits (see section 5.3).
Slovenian: V raziskavah o vplivu na razmnoževanje, ki so jih izvajali pri brejih podganah in kuncih, niso odkrili zaznavne teratogenosti (glejte poglavje 5.3).
English: Patients with moderate to severe elevations (ASAT or ALAT > 5 ULN) should be permanently discontinued from nevirapine.
Slovenian: Vsem z zmerno ali močno povečanimi vrednostmi (ASAT ali ALAT > 5-kratna zgornja mejna normalna vrednost) pa moramo nevirapin trajno ukiniti.
English: Children three years and older and adolescents
Slovenian: Otroci, starejši od 3 let in mladostniki
English: The isolated rash should be closely monitored (see section 4.4).
Slovenian: Posamezna mesta z izpuščajem je treba natančno opazovati (glejte poglavje 4.4).
English: Each tablet contains 200 mg nevirapine.
Slovenian: Ena tableta vsebuje 200 mg nevirapina.
English: The double non-nucleoside study 2 NN was a randomised, open-label, multicentre prospective study comparing the NNRTIs nevirapine, efavirenz and both medicinal products given together.
Slovenian: Dvojna nenukleozidna študija 2NN je bila odprta, multicentrična prospektivna študija pri naključno izbranih bolnikih, v kateri so primerjali nenukleozidni zaviralec reverzne transkriptaze nevirapin, efavirenz in obe zdravili pri hkratni uporabi.
English: In this study, no Grade 3 or 4 rash was observed in either treatment group.
Slovenian: V tej študiji noben bolnik v nobeni skupini ni imel izpuščaja 3. ali 4. stopnje.
English: The following adverse reactions have also been reported when nevirapine has been used in combination with other anti-retroviral agents: pancreatitis, peripheral neuropathy and thrombocytopaenia.
Slovenian: Med dajanjem nevirapina v kombinaciji z drugimi protiretrovirusnimi zdravili so poročali o naslednjih neželenih učinkih: pankreatitisu, periferni nevropatiji in trombocitopeniji.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/007 (30 tablets, bottle) EU/1/97/055/008 (30 tablets, blister) EU/1/97/055/009 (90 tablets, blister)
Slovenian: EU/1/97/055/007 (30 tablet, plastenka) EU/1/97/055/008 (30 tablet, pretisni omot) EU/1/97/055/009 (90 tablet, pretisni omot)
English: EU/1/97/055/003 [120 tablets]
Slovenian: EU/1/97/055/003 [120 tablet]
English: After 14 days, the usual dose is one 400 mg prolonged-release tablet once a day.
Slovenian: Običajen odmerek po 14 dneh je ena tableta s podaljšanim sproščanjem po 400 mg enkrat na dan.
English: Ketoconazole 400 mg QD
Slovenian: Ketokonazol 400 mg na dan
English: The mean peak plasma concentration of nevirapine was 2,060 ng/ml measured at a mean 24.5 hours after administration of 400 mg Viramune prolongedrelease tablets.
Slovenian: Srednja največja koncentracija nevirapina v plazmi je bila 2.060 ng/ml, merjena po srednjem času 24,5 ure po dajanju 400 mg zdravila Viramune tablete s podaljšanim sproščanjem.
English: Oral hormonal contraceptives should not be used as the sole method of contraception in women taking Viramune (see section 4.4).
Slovenian: Ženske, ki jemljejo zdravilo Viramune, hormonskih metod kontracepcije ne smejo uporabljati kot edino metodo kontracepcije (glejte poglavje 4.4).
English: 3 or in adult males with CD4 cell counts greater than 400 cells/mm
Slovenian: 3 in odraslih moških s številom celic CD4 nad 400 celic mm
English: No significant effect on rifabutin and Viramune mean PK parameters is seen.
Slovenian: Ni pomembnega učinka na srednje vrednosti farmakokinetičnih parametrov rifabutina in zdravila Viramune.
English: Carefully read the package leaflet of all other HIV medicinal products you are taking in combination with Viramune.
Slovenian: Natančno preberite navodila za uporabo vseh drugih zdravil za zdravljenje okužbe s HIV, ki jih boste jemali v kombinaciji z zdravilom Viramune.
English: Furthermore, combining the following compounds with Viramune is not recommended: efavirenz, ketoconazole, delavirdine, etravirine, rilpivirine, elvitegravir (in combination with cobicistat), atazanavir (in combination with ritonavir), boceprevir; fosamprenavir (if not co-administered with low dose ritonavir) (see section 4.5).
Slovenian: Odsvetovano je tudi kombiniranje zdravila Viramune z naslednjimi spojinami: efavirenz, ketokonazol, delavirdin, etravirin, rilpivirin, elvitegravir (v kombinaciji s kobicistatom), atazanavir (v kombinaciji z ritonavirjem), boceprevir; fosamprenavir (če ga ne dajemo hkrati z majhnimi odmerki ritonavirja) (glejte poglavje 4.5).
English: Sorbitol: Viramune oral suspension contains 162 mg of sorbitol per ml.
Slovenian: Sorbitol: Zdravilo Viramune peroralna suspenzija vsebuje 162 mg sorbitola v mililitru.
English: Granulocytopenia is commonly associated with zidovudine.
Slovenian: Z zidovudinom pogosto povezujejo granulocitopenijo.
English: Nevirapine: there was no significant difference in nevirapine pharmacokinetic parameters.
Slovenian: Nevirapin: farmakokinetični parametri nevirapina se niso pomembno spremenili.
English: Rifampicin 600 mg QD
Slovenian: Rifampicin 600 mg na dan
English: Viramune oral suspension should be used within 6 months after first opening of the bottle.
Slovenian: Peroralno suspenzijo Viramune je treba po prvem odpiranju plastenke porabiti v 6 mesecih.
English: Changes of body fat may occur in patients receiving combination antiretroviral therapy.
Slovenian: Pri bolnikih, ki prejemajo kombinirano protivirusno zdravljenje, lahko pride do sprememb telesnega maščevja.
English: Cross resistance to delavirdine and efavirenz is expected after virologic failure with nevirapine.
Slovenian: Pričakovana posledica virološkega neuspeha z nevirapinom je navzkrižna odpornost proti delavirdinu in efavirenzu.
English: Patients should be instructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
Slovenian: Bolnike je treba opozoriti, da ne smejo začeti jemati zdravila Viramune tablete s podaljšanim sproščanjem, dokler ne izgine izpuščaj, ki se je pojavil med 14-dnevnim uvajalnim obdobjem zdravljenja z zdravilom Viramune s takojšnjim sproščanjem.
English: Some risk factors for developing serious cutaneous reactions have been identified; they include failure to follow the initial dosing during the lead-in period and a long delay between the initial symptoms and medical consultation.
Slovenian: Znanih je nekaj dejavnikov tveganja za razvoj resnih kožnih reakcij, med njimi neupoštevanje začetnega odmerjanja v uvajalnem obdobju zdravljenja in daljši odlog od pojava prvih simptomov do obiska zdravnika.
English: Concomitant prednisone use (40 mg/day for the first 14 days of Viramune immediate-release administration) has been shown not to decrease the incidence of nevirapine-associated rash, and may be associated with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy.
Slovenian: Pokazalo se je, da sočasna uporaba prednizona (40 mg na dan prvih 14 dni zdravljenja z zdravilom Viramune s takojšnim sproščanjem) ne zmanjša pogostnosti izpuščaja, ki ga povzroča nevirapin, možno pa je, da je povezana s povečano pogostnostjo in resnostjo izpuščaja prvih 6 tednov zdravljenja z nevirapinom.
English: Nevirapine has not been specifically investigated in patients over the age of 65.
Slovenian: Nevirapina niso posebej preskušali pri bolnikih nad 65 let.
English: Itraconazole AUC  0.39 Itraconazole Cmin  0.13
Slovenian: AUC itrakonazola  0,39 Cmin itrakonazola  0,13
English: The risk of hepatic reactions is greatest in the first 6 weeks of therapy.
Slovenian: Nevarnost jetrnih reakcij je največja prvih 6 tednov zdravljenja.